CD47 and neoplasm: On the ground, Xie et al. (2020) found that BP-based PTT plus in combination with anti-CD47 antibodies (aCD47) can prompt the repolarization of tumor-associated macrophages (TAMs) from M2-like to M1-like macrophages, block the “do not eat me” signal of CD47-SIRPα in tumor cells and promote phagocytosis of macrophages (Figure 4B).